Next Article in Journal
Host Cell Binding Mediated by Leptospira interrogans Adhesins
Previous Article in Journal
Detection and pH-Thermal Characterization of Proteinases Exclusive of Honeybee Worker-Fate Larvae (Apis mellifera L.)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 24
10.3390/ijms232415549
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Lysosomal Acid Lipase Deficiency: Genetics, Screening, and Preclinical Study

by
Ryuichi Mashima
1,* and
Shuji Takada
2
1
Department of Clinical Laboratory Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan
2
Department of Systems BioMedicine, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(24), 15549; https://doi.org/10.3390/ijms232415549
Submission received: 16 November 2022 / Revised: 4 December 2022 / Accepted: 6 December 2022 / Published: 8 December 2022
(This article belongs to the Section Molecular Genetics and Genomics)
Versions Notes

Abstract

:
Lysosomal acid lipase (LAL) is a lysosomal enzyme essential for the degradation of cholesteryl esters through the endocytic pathway. Deficiency of the LAL enzyme encoded by the LIPA gene leads to LAL deficiency (LAL-D) (OMIM 278000), one of the lysosomal storage disorders involving 50–60 genes. Among the two disease subtypes, the severe disease subtype of LAL-D is known as Wolman disease, with typical manifestations involving hepatomegaly, splenomegaly, vomiting, diarrhea, and hematopoietic abnormalities, such as anemia. In contrast, the mild disease subtype of this disorder is known as cholesteryl ester storage disease, with hypercholesterolemia, hypertriglyceridemia, and high-density lipoprotein disappearance. The prevalence of LAL-D is rare, but several treatment options, including enzyme replacement therapy, are available. Accordingly, a number of screening methodologies have been developed for this disorder. This review summarizes the current discussion on LAL-D, covering genetics, screening, and the tertiary structure of human LAL enzyme and preclinical study for the future development of a novel therapy.

1. Introduction

Lysosomal acid lipase deficiency (LAL-D) (OMIM 278000) is a lysosomal storage disorder (LSD) characterized by an accumulation of cholesteryl esters and triglycerides in the lysosome [1,2,3,4,5,6]. A severe disease subtype of LAL-D is called Wolman disease, manifesting through various symptoms, such as hepatomegaly, splenomegaly, vomiting, diarrhea, adrenal calcification, and hematopoietic disorders, including anemia. Patients typically fail to survive beyond two years [7,8,9]. A mild disease subtype of LAL-D is called cholesteryl ester storage disease (CESD). In this case, patients suffer from hypercholesterolemia, hypertriglyceridemia, high-density lipoprotein (HDL) deficiency, and dysregulated lipid deposition [7]. Patients affected with CESD survive into adulthood. The current understanding of LAL-D is that this disorder is caused by a pathogenic mutation of the LIPA gene on chromosome 10q23.2-q23.3 with a very wide spectrum of clinical manifestations rather than two separate disorders. These manifestations are associated with no to low enzyme activity of LAL [10]. An elevation of enzyme activity of transaminases in the liver, such as ALT and AST, is considered a surrogate marker. Although changes in these alone may not provide a conclusive diagnosis, this evidence helps to make an accurate diagnosis. Biochemically, LAL is capable of degrading lipids such as cholesteryl esters, triglycerides, and retinyl esters. To assist diagnosis of LAL-D, an identification of adrenal calcification using imaging diagnosis with CT was used [11,12].
There are several treatment options for LAL-D. One is enzyme replacement therapy (ERT), in which patients receive a recombinant enzyme agent biweekly. The intravenously infused enzyme agent is then taken up by cells at or near the site of the disorder. Biochemically, the enzyme targets the lysosome in a mannose-6-phosphate-dependent manner. This mechanism is called a cross correction, a commonly observed biochemical process of the cellular intake of LSD enzymes [13,14]. An enzyme agent for LAL-D was approved by the FDA in 2015 [15,16]. A combination therapy of ERT and hematopoietic stem cell transplantation (HSCT) can be considered depending on the case [17]. In LAL-D, dietary substrate reduction may be performed combined with ERT or HSCT [17] by eliminating cholesteryl esters and triglycerides from the diet.
This Review aims to summarize recently published data within the last 5 years. In particular, great progress has been made in: (i) the understanding of the genetics of pathogenesis of LAL-D based on screening by both genetic and biochemical techniques; (ii) the tertiary structure of LIPA protein; (iii) the phenotype of animals of Lipa-deficient mice. Although these data are studied in each specific research area in an individually distinct manner, integration of them would enhance the benefit for the affected individuals with the possible development of a novel therapy with evidence. Specifically, for example, an accumulation of genetic data increases the accuracy of identification of a Wolman patient who needs to commence an immediate initiation of therapy. An understanding of LIPA enzyme structure would provide a wider chance of drug development. The results of the animal study would provide a variety of phenotypes in LAL-D-deficient patients, including both Wolman and CESD. Note that important references prior to this period were also included in order to help understand the historical background of LAL-D research.

2. Genetics

2.1. Prevalence

LAL-D is a rare disease [18]. A meta-analysis study estimated that the frequency of LAL-D was 1 in 177,000 [18]. In this study, the frequency of LAL-D was reported to be low among Finnish, East Asian, and South Asian patients and high among non-Finnish European patients. The number of mutations known is increasing; there are currently over 130 variants [1]. Overall, 50–60% of pathogenic alleles are linked to the E8SJM mutation. Except for this mutation, most mutations occur by chance. In other words, there is no evidence that recombination, large deletion, or other translocation occurs in the LIPA gene at a high frequency.

2.2. E8SJM (c.G894A; p.delS275_Q298)

There is a characterized pathogenic mutation in exon 8 (c.G894A; p.delS275_Q298) (Table 1) [1,16,19]. This is a mutation at the splicing joint of exon 8, leading to its splicing abnormality. As a result, the mutated LAL protein without enzyme activity, lacking a short peptide with 24 amino acids, was generated as a mature protein. In the homozygote of the mutant E8SJM, small residual enzyme activity is reported, which occurs due to the generation of wild-type enzymes by an incorrect splicing of the pathogenic genome [1].

2.3. Single Nucleotide Polymorphism (SNP)

There are two SNPs on exon 2: rs1051338 (c.A46C; p.T16P) and rs1051339 (c.G67A; p.G23R) (Table 1). The mutation of the LIPA gene involving these two SNPs causes alterations of amino acid sequences on the signal peptide of the LIPA transcript, leading to impaired lysosomal targeting and instability of a wild-type LAL enzyme [23]. Consistently, there is no evidence of pathogenicity in these genomic alterations.

3. Diagnosis and Screening

3.1. Biochemical Assay

LAL is a lysosomal enzyme that is active in acidic pH. Due to the presence of multiple isozymes of lipase in vivo [21,22], selective quantification of LAL enzyme activity from other lipases, such as lipoprotein lipase, is expected. Hamilton et al. developed a LAL assay using the LAL-specific inhibitor Lalistat-2 in dried blood spot (DBS) with 4-methylumbelliferone (4-MU)-based fluorometric quantification [10,29]. In this assay, the LAL enzyme activity was calculated as a Lalistat-2-inhibitable enzyme assay. This protocol is widely used in clinical laboratories [30,31]. Several populations of hepatic disorders, such as fatty liver, cirrhosis, and dyslipidemia, were screened by high-risk screening. Subsequently, an LAL-specific substratewas developed [32]. This substrate was successfully applied to LC-MS/MS [32,33].

3.2. Surrogate Markers

Surrogate markers are defined as biomarkers that change their concentration under pathophysiological conditions but are not directly associated with the cause of the disease. In LAL-D, elevated liver enzymes, such as ALT and AST, act as surrogate markers [15]. An elevation in cholesterol is associated with LAL-D [17]. Because elevation of these alone does not provide any conclusive results, an enzyme assay for LAL-D should be performed for diagnosis. Consistent with cholesterol accumulation, recent studies suggest that cholesterol 3β,5α,6β-triol could also be a reliable biomarker for LAL-D [34,35].

3.3. High-Risk Screening

High-risk screening is used to identify affected individuals in a relatively small population according to a range of criteria, such as age, ethnicity, or specific disease (e.g., familial hypercholesterolemia) (Table 2 and Table 3). The advantage of high-risk screening is that it increases the chance of patient identification. In such cases, the study was designed to identify at least one patient in the testing population. Therefore, the choice of population is a key determinant of the study design. Although previous studies preferred to opt for a biochemical assay, possibly due to its affordability, some current studies prefer a genetic assay, possibly due to a lack of quantitative biomarkers for diagnosis.

3.3.1. Genetic High-Risk Screening

To understand the identification of LAL-D-affected individuals, several high-risk screening studies have been performed (Table 2). In cohort-based studies, an earlier study identified a high E8SJM mutation prevalence in the German population [18,19,27]. Due to the association between lipidemia and LAL-D, subsequent studies have been designed to identify LIPA variants in dyslipidemia. For example, a U.K. study demonstrated that a population with familial hypercholesterolemia (FH) and no pathogenic mutations of LDLR, ApoB, and Pcsk9 contained LAL-D-affected patients [23,24].
Table
Table 2. High-risk screening for LAL-D using genetic assay.
Table 2. High-risk screening for LAL-D using genetic assay.
MethodYearCountryAuthorPopulationn LDLRApoBPcsk9APOELDLRAPABCG5ABCG8LIPASTAP1OthersRef.
TotalChildrenAdults
NGS+Sanger2022SloveniaSustar, UFH6696690189 (LDLR+ApoB+Pcsk9)NRNRNRNR3NR [20]
NGS2021NetherlandsReeskamp, LFFH152801528227 (LDLR+ApoB+Pcsk9)00020NR [36]
NGS+Sanger2021RussiaMiroshnikova, VVSuspected FH5928312451NR032 (ApoB+ABCG8)1NR [22]
NGS+Sanger2020Brazilde Paiva Silvino, JPFH143 (a)Combined511100000 [37]
NGS2020ArgentinaCorral, PFH2460246121 (ApoB+ApoE)NR1 (ApoB+ApoE)NRNRNR1NR [38]
NGS+Sanger+TaqMan2019Gran Canaria (Spain)Sánchez-Hernández, RMFH70070411100NRNR10 [39]
NGS+Sanger2018SloveniaGroselj, UFH170170049270NRNRNRNR1NR [40]
NGS2018SloveniaCorral, PHypercholesterolemia690692030207 (ABCG5+ABCG8)2NRCYP27A1(3), LIPC(1), LIPG(1), LPL(0), and SCARB1(1)[41]
Sanger2020PortugalMariano, CFH731311420282 (LDLR+ApoB+Pcsk9)NRNRNRNR3NR [42]
Sanger+TaqMan2019U.K.Ashfield-Watt, PFH6630663NRNRNRNRNRNRNR3NR [23]
Sanger2017PortugalChora, JRFH +dyslipidemia (b)750193557NRNRNRNRNRNRNR4NR [43]
Sanger2016NetherlandsSjouke, BFH27663213ExcludedExcludedNRNRNRNRNR6NR [24]
NR, not reported; FH, Familial hypercholesterolemia. (a) 32 index cases and 111 relatives; (b) FH (n = 492) + dyslipidemia and/or liver steatosis (n = 258). Gene abbreviation: ABCG5, ATP binding cassette subfamily G member 5; ABCG8, ATP binding cassette subfamily G member 8; ApoB, apolipoprotein B; ApoE, apolipoprotein E; CYP, cytochrome; LDLR, low-density lipoprotein receptor; LDLRAP, low-density lipoprotein receptor accessory protein; LIPA, lipase A, lysosomal acid; LIPC, lipase C, hepatic type; LPL, lipoprotein lipase; Pcsk9, proprotein convertase subtilisin kexin 9; SCARB, scavenger receptor class B member; STAP1, signal transducing adaptor family member 1.
Sjouke et al. reported the results of high-risk screening of a population with phenotypically diagnosed FH subjects (n = 276; 213 adults and 63 children; 105 males (38.0%)) [24]. In this study, the aforementioned major variant and SNPs such as E8SJM (2 heterozygotes), c.A46C (p.T16P; rs1051338; 101 heterozygotes and 12 homozygotes), and c.G67A (p.G23R; rs1051339; 43 heterozygotes and 3 homozygotes) were reported. In addition, some minor SNPs such as c.683 T>C (p.F228S; rs2228159; 2 heterozygotes; possibly pathogenic); c.913 T>A (p.F305I; not registered; 1 heterozygote; possibly pathogenic); c.966+3 A>T (putative primary structure not reported; rs201242614; pathogenic) were identified (Table 1 and Table 2).
Sustar et al. reported a genetic high-risk screening as part of Slovenian universal FH screening [20]. The authors screened LAL-D as a secondary condition of FH-related hyperlipidemia. Among the 669 children with dyslipidemia, they identified three affected individuals with a homozygous E8SJM (c.G894A) mutation. The authors suggest a beneficial role of genetic screening in children, as it can provide earlier detection of individuals affected by rare dyslipidemia at the early stage of their lives. To distinguish LAL-D from FH, the elevated activity of transaminases, such as AST and ALT, can be used as a surrogate biomarker.
Miroshnikova et al. reported high-risk screening of FH by the genetic method in Russia [22]. The authors recruited 59 unrelated patients (n = 31 adults; n = 28 children/adolescents). FH-associated genetic mutation was detected in 58% (n = 18) of the adults and 89% (n = 25) of the children. As a result, they identified multiple LDLR variants with a small number of ApoB variants. Additionally, one case of the LIPA variant was identified in their study.
Corral et al. reported a high-risk screening of FH detection programs in Argentina (da Vinci Study) [38]. Among 246 hypercholesterolemic patients, 21 individuals with definite diagnoses were selected. This sample was genetically analyzed using NGS with an extended panel of 23 dyslipidemia-related genes. Among the 21 patients, more than half (n = 12) had a variation in LDLR. They also identified a LIPA variant. Six individuals (28%) had no apparent mutation in the NGS panel, which raised the possibility that novel genes not listed in the NGS panel could be involved.

3.3.2. Biochemical High-Risk Screening

Tebani et al. reported the results of a large-scale clinical screening of LAL-D in a French population (Table 3) [44]. In their study, the authors selected a population for clinical screening based on unexplained hepatomegaly, an increase in transaminase activity, disturbed serum lipid profile with or without splenomegaly, gastrointestinal dysfunction, or hepatic microvascular steatosis/fibrosis/cirrhosis. The study was performed between 2015 and 2019, and the average ages of men (n = 2494) and women (n = 1690) in the sample were 44.88 ± 20.49 and 42.78 ± 22.56 years, respectively. The study also included children under two years of age (n = 157), both male and female.
The authors reported a mean LAL activity of 0.89 ± 0.54 nmol/punch/h in the DBS samples [44]. Overall, the study identified six Wolman- and 13 CESD-affected individuals. Wolman patients involved 2 males and 4 females with an average age at diagnosis of 3.12 ± 4.08 months. CESD patients involved 4 males and 9 females with an average age at diagnosis of 22.42 ± 18.23 years. Wolman-affected individuals were only detected in children, and CESD-affected individuals were in adults, respectively. The detected mutations included nonsense, frame shift, and splicing variants; the spectra of the pathogenic mutations in Wolman and CESD were distinct. Notably, the common variant E8SJM/c.G894A, which accounted for 12 out of 34 mutated alleles, was found only in the CESD-affected individuals. Note that no difference was observed in LAL activity between the Wolman- and CESD-affected individuals.
Mayanskiy et al. reported the LAL activity of DBS in a Russian population [45]. In their study, the authors researched a sample of 537 LAL-D-suspected individuals undergoing clinical screening between June 2016 and July 2018. The sample included 239 children (44.5%) under five years of age. The genetic analysis identified affected (n = 6) individuals and carriers. To obtain further insight into the prevalence of E8SJM/c.G894A, a merged population, including the six samples identified in this study and 12 previously diagnosed samples, were examined. In this pool, the authors identified 16 individuals who had this mutation with six homozygotes. An inverse correlation of LAL-D enzyme activity among patients under 10–15 years of age was reported.
Originally, Hamilton et al. reported the inclusion of Lalistat-2 in DBS to quantify LAL enzyme activity [10,29]. However, Mayanskiy et al. reported a kinetic assay of the LAL enzyme without Lalistat-2, showing 100% sensitivity of LAL-D-affected individuals (n = 6) and near-complete sensitivity of non-LAL-D individuals (103 out of 105) [45]. As long as assay specificity is guaranteed and assay equipment is available, the latter assay can be useful. Notably, under this assay condition, the LAL-D-affected individuals showed approximately 20% lower non-LAL-derived basal activity, implying attenuation of these activities in LAL-D patients.
Table
Table 3. High-risk screening for LAL-D enzyme using DBS.
Table 3. High-risk screening for LAL-D enzyme using DBS.
MethodYearCountryAuthorPopulationn Affected Ref.
TotalChildrenAdultWolmanCESD
4MU2021FranceTebani, AClinical screening41741574017613[44]
4MU2019RussiaMayanskiy, NClinical screening5372392986 positives[45]
4MU2018U.K.Reynolds, TM↓HDL; ↑ALT1825Combined00[46]
4MU2017ItalyTovoli, FNAFLD159015900[47]
4MU2017ItalyVespasiani-Gentilucci UHealthy subjects172017200[29]
4MU2016ItalyVespasiani-Gentilucci, UCirrhosis + Healthy controls252025200[48]
4MU2016ItalySelvakakumar, PKCChildren with NAFLD168168000[49]
4MU2016IsraelShteyer, ECirrhosis without known etiology22Combined00[50]
4MU2015ItalyBaratta, FAdult NAFLD240024000[51]
4MU2014JapanDairaku TCESD + Normal control65Not described07[28]
ALT, alanine transaminase; HDL, high-density lipoprotein; NAFLD, nonalcoholic fatty liver disease.

3.4. Newborn Screening

Newborn screening is used to identify disease-affected individuals at an early age after birth [52]. Such screening was initially proposed by Dr. Guthrie in the 1960s for the treatment of phenylketonuria [53]. The earlier assays used microbial procedures; however, the current assays use modern instruments for the quantification of biomarkers, including metabolites and enzyme activity. Today, newborn screening is implemented with a variety of metabolic disorders, including LSDs and immune and neurological disorders [54,55,56], which necessitates a robust screening methodology and disease-specific therapy. In addition, the prevalence is another factor to be considered.
A type of blood formulation called DBS has been used for newborn screening. The application of DBS for quantification includes amino acids and acylcarnitines [53], LSD enzymes [52,54,56], T cell receptor excision circle (TREC), and survival motor neuron (SMN) [57,58]. As the target biomarker (metabolites, enzyme activity, genome, etc.) is stable under the specified transportation conditions, the usefulness of DBS for newborn screening (NBS) has been widely appreciated. As listed in Table 3, the LAL enzyme remains active when DBS is properly prepared. In LAL-D, no newborn screening is currently performed. Based on the success of high-risk screening in Russia [45] and France [44], newborn screening for LAL-D is increasingly demanded.

4. Tertiary Structure of Human LAL Protein

Until recently, the structure of the human LAL enzyme has been only postulated according to two established structures of lipases, such as human gastric lipase [59] and dog gastric lipase [60]. In general, lipases are involved in α/β hydrolase superfamily similar to serine proteases, and this superfamily has a conserved amino acid triad consisting of serine, histidine, and asparagine. These three conserved amino acids are also found in human gastric lipase and human LAL as well. Human gastric lipase has a core domain and a cap domain with a lid subdomain [59]. The lid subdomain is capable of translocating between closed and open states. Based on the similarity of the primary structure of the human LAL enzyme, it has been postulated that human LAL might have a similar structure. Homology-based modeling is a software-based strategy that allows the prediction of the pathogenesis of uncharacterized mutants for CESD and Wolman disease based on the primary structure of the human LAL enzyme [61].
Recently, Rajamohan et al. reported the crystal structure of the human LAL protein [62]. Overall, the structure of the human LAL enzyme is found to be similar to other members of the hydrolase superfamily involving human gastric lipase. Human LAL enzyme has the core domain consisting of a central β-sheet composed of eight strands and two sets of three helices on each side. The cap domain of the human LAL enzyme contains a lid structure (residues 215–244) that adapts a closed conformation. A comparison of the lid-open form and the lid-closed form of human LAL enzyme revealed that Pro214 and Gly245 act as hinges between the cap and core domain structures. A biochemical experiment deleting the 7-amino acid sequence (resides 238–244: NLCFLLC) significantly impaired LAL enzyme activity at acidic pH [62]. Based on structural data, this inactivation is caused by an impaired binding of the mutant protein and a substrate. The proper activation only occurred in wild-type enzymes at acidic pH, whereas a weak binding of the enzyme and substrate was usually observed at neutral pH.
An H274Y mutant is an identified LAL mutant identified in CESD-affected individuals [62]. The activity of the lipase enzyme in this mutant is less than 5%, but the structural rationale behind this phenomenon remains undiscovered [63]. Based on the newly reported structural data for the human LAL enzyme, His274 has been, for the first time, identified as a key amino acid interacting through hydrophobic interaction with Ser122 and Gln285 of the core domain. A molecular dynamics study revealed that this H274Y mutant had impaired flexibility of the putative lid subdomain in the LAL enzyme.
Finally, the E8SJM mutant, lacking a short sequence of 24 amino acids arising from exon skipping, has no enzyme activity [1,16,17]. According to the tertiary structure of the wild-type human LAL enzyme, this mutant lacks the abovementioned short sequence at the C-terminal region of the cap domain. In this case, the primary structures of the core domain and the lid subdomain remain intact, suggesting that a substantial alteration of the cap domain may be involved.

5. Phenotype of Lipa-Deficient Mice

Mice deficient in the Lipa gene have been used as the disease model of human pathology to understand its mechanism. In mice, three major phenotypes—hepatic lipid accumulation, immune modulation, and tumorigenesis—have been reported. As mentioned, abnormal lipid accumulation is a hallmark of LAL-D, including both Wolman and CESD [1]. Pancytopenia and hyper-inflammation, together with hypercytokinemia and hemophagocytic lymphohistiocytosis arising from the abnormality of immune cells, may be observed in Wolman disease [17]. Although, to a lesser extent, two cases of hepatocellular carcinoma were also reported in CESD [1]. Thus, these manifestations in humans could be recapitulated by Lipa-deficient mice. Less well characterized is the role of cholesterol accumulation in LAL-D and homeostatic gene expression relevant to lipid accumulation, immunity, and tumorigenesis.

5.1. Lipid Accumulation

Based on the existing data, the phenotype of the liver appears to be similar to that of CESD rather than Wolman (Table 4). Essentially, Lipa-deficient mice showed an increase in cholesteryl esters in their livers; however, the accumulation of triglycerides and retinoic acid appears to be inconclusive. According to the results of liver-specific Lipa deficiency, hepatic TG and RA remain unaltered in normal chow. However, an approximately 30% reduction of triglycerides in the liver in the liver-specific Lipa-cKO mice with a high-fat diet containing vitamin A at the age of five months [64]. These results clearly demonstrated that hepatic LAL plays a key role in CE metabolism in the liver, while hydrolysis of triglyceride and retinoic acid is mediated by uncharacterized lipase.

5.2. Immune Cells

In Wolman disease, impaired hematopoiesis, including anemia, is occasionally reported [1,51]. Considering that hepatomegaly is a common phenotype in humans and mice, extramedullary hematopoiesis, an alternative process of hematopoiesis other than the bone marrow, may be particularly important in humans [79]. The increasing proliferation ability of hematopoietic stem cells and granulocyte-monocyte progenitor cells of Lipa-deficient mice suggests an enhanced tyrosine kinase-mediated signaling pathway in these mice [69]. This observation is consistent with other immune cells in Lipa-deficient mice (Table 4).
Nguyen et al. reported the role of the Lipa gene in graft-versus-host disease (GVHD) [80]. The authors examined its role in the murine model of allogenic hematopoietic cell transplantation and found that this gene was essential for donor T cell survival, differentiation, and alloreactivity in the GVHD’s target organs but not in lymphoid organs. In the Lipa-deficient T cells, a preferential differentiation of T cells into Th1 and Th17 with an impaired differentiation to the regulatory T cells, both of which lead to anergic conditions in target organs, was observed, which can, at least partially, be explained by an enhanced susceptibility of the Lipa-deficient mice to oxidative stress. This observation was recapitulated by suppressing LAL enzyme activity by a small molecule, such as orlistat. Thus, the results demonstrated that LAL plays an important role in controlling GVHD and tumor growth after allogenic hematopoietic cell transplantation.

5.3. Tumorigenesis

The role of the Lipa gene in tumorigenesis has been studied in murine models [73,77,81]. In Lipa-deficient mice, transplanted melanoma grew rapidly compared to controls. The reason for this can be associated with enhanced tumor metastasis [77]. To obtain further insight into this observation, enhanced angiogenesis of endothelial cells in Lipa-deficient mice has been suggested [73]. Notably, there is a case study reporting cholangiocarcinoma suffered by a CESD patient with a compound heterozygote of the LIPA gene with c.G894A and ΔC(673–675) [82,83]. In this case, a massive accumulation of histiocytes was noted.
Liu et al. reported an anti-tumor role of the Lipa gene in the ER stress-mediated mechanism [84]. The authors were the first to identify a stereo-specific small molecule (ERX-41) with high binding properties to LAL protein. In their study, they showed that ERX-41 is a novel ER localization regulator through the LAL protein without modulating its enzyme activity.

6. Treatment

Since enzyme replacement therapy was approved in 2015 in the U.S., patients in most European and Asian countries have also had access to this agent [15]. Apart from that, dietary substrate reduction therapy is an emerging therapy that successfully reduces lipid levels in patients by lowering the lipid content in their diet when used with ERT or HSCT [17]. For CESD-affected individuals, the use of pharmacological agents, including statins and ezetimibe, has been considered [1]. Liver transplantation has also been considered [1]. Apart from these established treatment options, a novel therapy, including gene therapy using adeno-associated virus (AAV), has been examined in the murine model [85].

6.1. Enzyme Replacement Therapy

Several preclinical studies have been performed using Lipa-deficient mice (Table 5), in which the therapeutic effect of intravenously administering the purified recombinant LAL protein was studied. For example, Sun et al. reported that Lipa-deficient mice were treated with different levels of LAL enzyme, ranging from 0.8 to 3.2 mg/kg [86]. Under these experimental settings, the lifespan of the treated rodents was extended by 52 and 92 days at 0.8 mg/kg and 3.2 mg/kg, respectively, and the accumulation of cholesterol and triglyceride in their livers and spleens decreased. At 10 mg/kg, the treated mice showed normalized organ sizes and liver, spleen, and intestine histology. These results demonstrated that the recombinant human LAL enzyme was active and safe in the mouse model. For the development of an enzyme agent for clinical use, a rat model was used [87].

6.2. Gene Therapy

Lopresti et al. reported the effectiveness of AAV-mediated gene therapy in the Lipa-deficient model [85]. In their study, the thyroxine-biding globulin-driven LIPA gene was carried in AAV encapsulated with the AAV8 serotype (an established serotype that targets the liver). To mimic the nonalcoholic fatty liver disease (NAFLD) condition, an FPC diet (a high-fat diet with additional fructose, palmitate, and cholesterol) was administered. In this model, a cohort of mice (9 weeks old) was divided into two groups at week 0, followed by AAV administration at 5 × 1011 vector copies/mouse through a retroorbital injection. Then, these mice were further divided into two groups at week 1: one was treated with the common Western diet, and the other one was treated with the control diet. At week 16 (26 weeks old), the mice showed the same body weight in males, with an increased liver weight following the Western diet treatment. Under this treatment condition, both the activity and protein of LAL in the liver were elevated in the AAV-administered animals. Most strikingly, the authors reported a larger accumulation of Kupffer cells in the LIPA-administered mice with the Western diet compared to the GFP-administered control mice. This observation was reconciled by increased autophagocytosis with elevated LC3-II protein expression in the AAV-administered mice.
Lam et al. reported a therapeutic effect of rscAAVrh74-mediated LIPA expression [91]. In their study, the therapeutic vector was administered at post-natal day 2 (P2) (neonate) through the facial vein in a sample of young mice (P60) and through the tail vein in adult mice (P120). The elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzyme activity in the Lipa-deficient mice was significantly decreased at P60 and P120 when the vector was administered at a dose of 8.4 × 1013 vector genomes (vg) per kilogram (vg/kg) intravenously. They also reported a wide distribution of the AAV vector in the liver, spleen, intestine, and lymph node at P60 and P120, while in the heart and lung, it was comparable to the mice that were administered at P2. Similarly, LAL enzyme activity was detected in the liver at P60 and P120, while it was only significantly elevated in the spleen at P120. In addition to enzyme activity, triglyceride, a major class of lipids in the liver, is another measure for AAV-mediated treatment. When AAV was administered at P2, an attenuated level of triglycerides was observed in the liver at the age of six months. Similarly, other parameters, such as cholesterol level in the liver and spleen and triglycerides in the spleen, were reduced when AAV was administered at P120. These results indicate that a large amount of vector (8.4 × 1013 vg/kg) was required for the best therapeutic effect in the mouse model. Notably, hepatic inflammation was also attenuated when the AAV vector was administered in a dose-dependent manner at a later stage.

7. Future Perspectives

As mentioned earlier, LAL-D is a rare disorder with several treatment options. The prevalence of LAL-D may vary depending on the ethnicity and disease population. The outcome of high-risk FH screening demonstrated that this population contains a large number of LAL-D-affected individuals. To implement screening for LAL-affected individuals, an estimation of the prevalence is required.

Author Contributions

Conceptualization, R.M.; writing—original draft preparation, R.M.; writing—review and editing, R.M. and S.T.; funding acquisition, R.M. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by a grant-in-aid from JSPS (22K07927) and AMED (22ae0201004h0005) to RM.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bernstein, D.L.; Hülkova, H.; Bialer, M.G.; Desnick, R.J. Cholesteryl ester storage disease: Review of the findings in 135 reported patients with an underdiagnosed disease. J. Hepatol. 2013, 58, 1230–1243. [Google Scholar] [CrossRef] [Green Version]
  2. Maciejko, J.J. Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency. Am. J. Cardiovasc. Drugs 2017, 17, 217–231. [Google Scholar] [CrossRef] [PubMed]
  3. Gomaraschi, M.; Bonacina, F.; Norata, G.D. Lysosomal Acid Lipase: From Cellular Lipid Handler to Immunometabolic Target. Trends Pharmacol. Sci. 2019, 40, 104–115. [Google Scholar] [CrossRef] [PubMed]
  4. Li, F.; Zhang, H. Lysosomal Acid Lipase in Lipid Metabolism and Beyond. Arter. Thromb. Vasc. Biol. 2019, 39, 850–856. [Google Scholar] [CrossRef]
  5. Aguisanda, F.; Thorne, N.; Zheng, W. Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development. Curr. Chem. Genom. Transl. Med. 2017, 11, 1–18. [Google Scholar] [CrossRef] [PubMed]
  6. Pastores, G.M.; Hughes, D.A. Lysosomal Acid Lipase Deficiency: Therapeutic Options. Drug Des. Dev. Ther. 2020, 14, 591–601. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Pericleous, M.; Kelly, C.; Wang, T.; Livingstone, C.; Ala, A. Wolman’s disease and cholesteryl ester storage disorder: The phenotypic spectrum of lysosomal acid lipase deficiency. Lancet Gastroenterol. Hepatol. 2017, 2, 670–679. [Google Scholar] [CrossRef] [PubMed]
  8. Jones, S.A.; Valayannopoulos, V.; Schneider, E.; Eckert, S.; Banikazemi, M.; Bialer, M.; Cederbaum, S.; Chan, A.; Dhawan, A.; Di Rocco, M.; et al. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. Genet. Med. 2016, 18, 452–458. [Google Scholar] [CrossRef] [Green Version]
  9. Jones, S.A.; Rojas-Caro, S.; Quinn, A.G.; Friedman, M.; Marulkar, S.; Ezgu, F.; Zaki, O.; Gargus, J.J.; Hughes, J.; Plantaz, D.; et al. Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: An open-label, multicenter, dose-escalation study. Orphanet J. Rare Dis. 2017, 12, 25. [Google Scholar] [CrossRef] [Green Version]
  10. Hamilton, J.; Jones, I.; Srivastava, R.; Galloway, P. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin. Chim. Acta 2012, 413, 1207–1210. [Google Scholar] [CrossRef]
  11. Shenoy, P.; Karegowda, L.; Sripathi, S.; Mohammed, N. Wolman disease in an infant. BMJ Case Rep. 2014, 2014, bcr2014203656. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Foladi, N.; Aien, M.T. CT features of Wolman disease (lysosomal acid lipase enzyme deficiency)—A case report. Radiol. Case Rep. 2021, 16, 2857–2861. [Google Scholar] [CrossRef] [PubMed]
  13. Platt, F.M.; D’Azzo, A.L.; Davidson, B.; Neufeld, E.F.; Tifft, C.J. Lysosomal storage diseases. Nat. Rev. Dis. Prim. 2018, 4, 27. [Google Scholar] [CrossRef] [PubMed]
  14. Ohira, M.; Kikuchi, E.; Mizuta, S.; Yoshida, N.; Onodera, M.; Nakanishi, M.; Okuyama, T.; Mashima, R. Production of therapeutic iduronate-2-sulfatase enzyme with a novel single-stranded RNA virus vector. Genes Cells 2021, 26, 891–904. [Google Scholar] [CrossRef] [PubMed]
  15. Burton, B.K.; Balwani, M.; Feillet, F.; Barić, I.; Burrow, T.A.; Grande, C.C.; Coker, M.; Consuelo-Sánchez, A.; Deegan, P.; Di Rocco, M.; et al. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N. Engl. J. Med. 2015, 373, 1010–1020. [Google Scholar] [CrossRef]
  16. Valayannopoulos, V.; Malinova, V.; Honzík, T.; Balwani, M.; Breen, C.; Deegan, P.B.; Enns, G.M.; Jones, S.A.; Kane, J.P.; Stock, E.O.; et al. Sebelipase alfa over 52weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. J. Hepatol. 2014, 61, 1135–1142. [Google Scholar] [CrossRef] [Green Version]
  17. Potter, J.E.; Petts, G.; Ghosh, A.; White, F.J.; Kinsella, J.L.; Hughes, S.; Roberts, J.; Hodgkinson, A.; Brammeier, K.; Church, H.; et al. Enzyme replacement therapy and hematopoietic stem cell transplant: A new paradigm of treatment in Wolman disease. Orphanet J. Rare Dis. 2021, 16, 235. [Google Scholar] [CrossRef]
  18. Carter, A.; Brackley, S.M.; Gao, J.; Mann, J.P. The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD. J. Hepatol. 2019, 70, 142–150. [Google Scholar] [CrossRef] [Green Version]
  19. Scott, S.A.; Liu, B.; Nazarenko, I.; Martis, S.; Kozlitina, J.; Yang, Y.; Ramirez, C.; Kasai, Y.; Hyatt, T.; Peter, I.; et al. Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups. Hepatology 2013, 58, 958–965. [Google Scholar] [CrossRef] [Green Version]
  20. Sustar, U.; Groselj, U.; Podkrajsek, K.T.; Mlinaric, M.; Kovac, J.; Thaler, M.; Torkar, A.D.; Skarlovnik, A.; Battelino, T.; Hovnik, T. Early Discovery of Children With Lysosomal Acid Lipase Deficiency With the Universal Familial Hypercholesterolemia Screening Program. Front. Genet. 2022, 13, 936121. [Google Scholar] [CrossRef]
  21. Pasta, A.; Borro, P.; Cremonini, A.L.; Formisano, E.; Tozzi, G.; Cecchi, S.; Fresa, R.; Labanca, S.; Djahandideh, A.; Sukkar, S.G.; et al. Effect of a common missense variant in LIPA gene on fatty liver disease and lipid phenotype: New perspectives from a single-center observational study. Pharmacol. Res. Perspect. 2021, 9, e00820. [Google Scholar] [CrossRef] [PubMed]
  22. Miroshnikova, V.V.; Romanova, O.V.; Ivanova, O.N.; Fedyakov, M.A.; Panteleeva, A.A.; Barbitoff, Y.A.; Muzalevskaya, M.V.; Urazgildeeva, S.A.; Gurevich, V.S.; Urazov, S.P.; et al. Identification of novel variants in the LDLR gene in Russian patients with familial hypercholesterolemia using targeted sequencing. Biomed. Rep. 2021, 14, 15. [Google Scholar] [CrossRef]
  23. Ashfield-Watt, P.; Haralambos, K.; Edwards, R.; Townsend, D.; Gingell, R.; Li, K.W.; Humphries, S.E.; McDowell, I. Estimation of the prevalence of cholesteryl ester storage disorder in a cohort of patients with clinical features of familial hypercholesterolaemia. Ann. Clin. Biochem. 2019, 56, 112–117. [Google Scholar] [CrossRef] [PubMed]
  24. Sjouke, B.; Defesche, J.C.; de Randamie, J.S.E.; Wiegman, A.; Fouchier, S.W.; Hovingh, G.K. Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis 2016, 251, 263–265. [Google Scholar] [CrossRef] [Green Version]
  25. Pullinger, C.R.; Stock, E.O.; Movsesyan, I.; Malloy, M.J.; Frost, P.H.; Tripuraneni, R.; Quinn, A.G.; Ishida, B.Y.; Schaefer, E.J.; Asztalos, B.F.; et al. Identification and metabolic profiling of patients with lysosomal acid lipase deficiency. J. Clin. Lipidol. 2015, 9, 716–726.e1. [Google Scholar] [CrossRef]
  26. Muntoni, S.; Wiebusch, H.; Jansen-Rust, M.; Rust, S.; Schulte, H.; Berger, K.; Pisciotta, L.; Bertolini, S.; Funke, H.; Seedorf, U.; et al. Heterozygosity for lysosomal acid lipase E8SJM mutation and serum lipid concentrations. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 732–736. [Google Scholar] [CrossRef] [PubMed]
  27. Muntoni, S.; Wiebusch, H.; Jansen-Rust, M.; Rust, S.; Seedorf, U.; Schulte, H.; Berger, K.; Funke, H.; Assmann, G. Prevalence of Cholesteryl Ester Storage Disease. Arter. Thromb. Vasc. Biol. 2007, 27, 1866–1868. [Google Scholar] [CrossRef] [PubMed]
  28. Pisciotta, L.; Tozzi, G.; Travaglini, L.; Taurisano, R.; Lucchi, T.; Indolfi, G.; Papadia, F.; Di Rocco, M.; D’Antiga, L.; Crock, P.; et al. Molecular and clinical characterization of a series of patients with childhood-onset lysosomal acid lipase deficiency. Retrospective investigations, follow-up and detection of two novel LIPA pathogenic variants. Atherosclerosis 2017, 265, 124–132. [Google Scholar] [CrossRef]
  29. Lukacs, Z.; Barr, M.; Hamilton, J. Best practice in the measurement and interpretation of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin. Chim. Acta 2017, 471, 201–205. [Google Scholar] [CrossRef] [PubMed]
  30. Dairaku, T.; Iwamoto, T.; Nishimura, M.; Endo, M.; Ohashi, T.; Eto, Y. A practical fluorometric assay method to measure lysosomal acid lipase activity in dried blood spots for the screening of cholesteryl ester storage disease and Wolman disease. Mol. Genet. Metab. 2014, 111, 193–196. [Google Scholar] [CrossRef]
  31. Vespasiani-Gentilucci, U.; D’Amico, J.; De Vincentis, A.; Tozzi, G.; Vorini, F.; Gallo, P.; Carotti, S.; Valentini, F.; Galati, G.; Dell’Unto, C.; et al. Platelet count may impact on lysosomal acid lipase activity determination in dried blood spot. Clin. Biochem. 2017, 50, 726–728. [Google Scholar] [CrossRef] [PubMed]
  32. Masi, S.; Chennamaneni, N.; Turecek, F.; Ronald Scott, C.; Gelb, M.H. Specific Substrate for the Assay of Lysosomal Acid Lipase. Clin. Chem. 2018, 64, 690–696. [Google Scholar] [CrossRef]
  33. Ohira, M.; Barr, M.; Okuyama, T.; Mashima, R. LC-MS/MS-based enzyme assay for lysosomal acid lipase using dried blood spots. Mol. Genet. Metab. Rep. 2022, 33, 100913. [Google Scholar] [CrossRef] [PubMed]
  34. Jiang, X.; Sidhu, R.; Porter, F.D.; Yanjanin, N.M.; Speak, A.O.; te Vruchte, D.T.; Platt, F.M.; Fujiwara, H.; Scherrer, D.E.; Zhang, J.; et al. A Sensitive and Specific LC-MS/MS Method for Rapid Diagnosis of Niemann-Pick C1 Disease from Human Plasma. J. Lipid Res. 2011, 52, 1435–1445. [Google Scholar] [CrossRef] [Green Version]
  35. Cooper, J.A.; Church, H.J.; Wu, H.Y. Cholestane-3β, 5α, 6β-Triol: Further Insights into the Performance of This Oxysterol in Diagnosis of Niemann-Pick Disease Type C. Mol. Genet. Metab. 2020, 130, 77–86. [Google Scholar] [CrossRef] [PubMed]
  36. Reeskamp, L.F.; Tromp, T.R.; Defesche, J.C.; Grefhorst, A.; Stroes, E.S.G.; Hovingh, G.K.; Zuurbier, L. Next-Generation Sequencing to Confirm Clinical Familial Hypercholesterolemia. Eur. J. Prev. Cardiol. 2021, 28, 875–883. [Google Scholar] [CrossRef] [PubMed]
  37. de Paiva Silvino, J.P.; Jannes, C.E.; Tada, M.T.; Lima, I.R.; de Fátima Oliveira Silva, I.; Pereira, A.C.; Gomes, K.B. Cascade Screening and Genetic Diagnosis of Familial Hypercholesterolemia in Clusters of the Southeastern Region from Brazil. Mol. Biol. Rep. 2020, 47, 9279–9288. [Google Scholar] [CrossRef]
  38. Corral, P.; Bañares, V.; Sáenz, B.; Zago, V.; Sarobe, A.; López, G.; Berg, G.; Schreier, L. Phenotype of Definite Familial Hypercholesterolemia with Negative Genetic Study in Argentina. Arch. Cardiol. Mex. 2020, 90, 130–136. [Google Scholar] [CrossRef]
  39. Sánchez-Hernández, R.M.; Tugores, A.; Nóvoa, F.J.; Brito-Casillas, Y.; Expósito-Montesdeoca, A.B.; Garay, P.; Bea, A.M.; Riaño, M.; Pocovi, M.; Civeira, F.; et al. The Island of Gran Canaria: A Genetic Isolate for Familial Hypercholesterolemia. J. Clin. Lipidol. 2019, 13, 618–626. [Google Scholar] [CrossRef]
  40. Groselj, U.; Kovac, J.; Sustar, U.; Mlinaric, M.; Fras, Z.; Podkrajsek, K.T.; Battelino, T. Universal Screening for Familial Hypercholesterolemia in Children: The Slovenian Model and Literature Review. Atherosclerosis 2018, 277, 383–391. [Google Scholar] [CrossRef]
  41. Corral, P.; Geller, A.S.; Polisecki, E.Y.; Lopez, G.I.; Bañares, V.G.; Cacciagiu, L.; Berg, G.; Hegele, R.A.; Schaefer, E.J.; Schreier, L.E. Unusual Genetic Variants Associated with Hypercholesterolemia in Argentina. Atherosclerosis 2018, 277, 256–261. [Google Scholar] [CrossRef] [PubMed]
  42. Mariano, C.; Alves, A.C.; Medeiros, A.M.; Chora, J.R.; Antunes, M.; Futema, M.; Humphries, S.E.; Bourbon, M. The Familial Hypercholesterolaemia Phenotype: Monogenic Familial Hypercholesterolaemia, Polygenic Hypercholesterolaemia and Other Causes. Clin Genet 2020, 97, 457–466. [Google Scholar] [CrossRef] [PubMed]
  43. Chora, J.R.; Alves, A.C.; Medeiros, A.M.; Mariano, C.; Lobarinhas, G.; Guerra, A.; Mansilha, H.; Cortez-Pinto, H.; Bourbon, M. Lysosomal Acid Lipase Deficiency: A Hidden Disease among Cohorts of Familial Hypercholesterolemia? J. Clin. Lipidol. 2017, 11, 477–484.e2. [Google Scholar] [CrossRef] [Green Version]
  44. Tebani, A.; Sudrié-Arnaud, B.; Boudabous, H.; Brassier, A.; Anty, R.; Snanoudj, S.; Abergel, A.; Abi Warde, M.T.; Bardou-Jacquet, E.; Belbouab, R.; et al. Large-scale screening of lipase acid deficiency in at risk population. Clin. Chim. Acta 2021, 519, 64–69. [Google Scholar] [CrossRef] [PubMed]
  45. Mayanskiy, N.; Brzhozovskaya, E.; Pushkov, A.; Strokova, T.; Vlasov, N.; Surkov, A.; Gundobina, O.; Savostianov, K. A kinetic assay of total lipase activity for detecting lysosomal acid lipase deficiency (LAL-D) and the molecular characterization of 18 LAL-D patients from Russia. JIMD Rep. 2019, 48, 75–82. [Google Scholar] [CrossRef] [Green Version]
  46. Reynolds, T.M.; Mewies, C.; Hamilton, J.; Wierzbicki, A.S. Identification of rare diseases by screening a population selected on the basis of routine pathology results—The PATHFINDER project: Lysosomal acid lipase/cholesteryl ester storage disease substudy. J. Clin. Pathol. 2018, 71, 608–613. [Google Scholar] [CrossRef]
  47. Tovoli, F.; Napoli, L.; Negrini, G.; D’Addato, S.; Tozzi, G.; D’Amico, J.; Piscaglia, F.; Bolondi, L. A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2017, 18, 1134. [Google Scholar] [CrossRef] [Green Version]
  48. Vespasiani-Gentilucci, U.; Gallo, P.; Piemonte, F.; Riva, E.; Porcari, A.; Vorini, F.; Tozzi, G.; Piccioni, L.; Galati, G.; De Vincentis, A.; et al. Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology. PLoS ONE 2016, 11, e0156113. [Google Scholar] [CrossRef] [Green Version]
  49. Selvakumar, P.K.C.; Kabbany, M.N.; Lopez, R.; Tozzi, G.; Alisi, A.; Alkhouri, N.; Nobili, V. Reduced lysosomal acid lipase activity—A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. Dig. Liver Dis. 2016, 48, 909–913. [Google Scholar] [CrossRef]
  50. Shteyer, E.; Villenchik, R.; Mahamid, M.; Nator, N.; Safadi, R. Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease. Int. J. Mol. Sci. 2016, 17, 312. [Google Scholar] [CrossRef]
  51. Baratta, F.; Pastori, D.; Del Ben, M.; Polimeni, L.; Labbadia, G.; Di Santo, S.; Piemonte, F.; Tozzi, G.; Violi, F.; Angelico, F. Reduced Lysosomal Acid Lipase Activity in Adult Patients with Non-Alcoholic Fatty Liver Disease. eBioMedicine 2015, 2, 750–754. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Peake, R.W.A.; Marsden, D.L.; Bodamer, O.A.; Gelb, M.H.; Millington, D.S.; Wijburg, F. Newborn Screening for Lysosomal Storage Disorders: Quo Vadis? Clin. Chem. 2016, 62, 1430–1438. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Lim, J.S.; Tan, E.S.; John, C.M.; Poh, S.; Yeo, S.J.; Ang, J.S.M.; Adakalaisamy, P.; Rozalli, R.A.; Hart, C.; Tan, E.T.H.; et al. Inborn Error of Metabolism (IEM) screening in Singapore by electrospray ionization-tandem mass spectrometry (ESI/MS/MS): An 8year journey from pilot to current program. Genet. Med. 2019, 21, 631–640. [Google Scholar] [CrossRef]
  54. Schielen, P.C.J.I.; Kemper, E.A.; Gelb, M.H. Newborn Screening for Lysosomal Storage Diseases: A Concise Review of the Literature on Screening Methods, Therapeutic Possibilities and Regional Programs. Int. J. Neonatal Screen. 2017, 3, 6. [Google Scholar] [CrossRef]
  55. Wasserstein, M.P.; Caggana, M.; Bailey, S.M.; Desnick, R.J.; Edelmann, L.; Estrella, L.; Holzman, I.; Kelly, N.R.; Kornreich, R.; Kupchik, S.G.; et al. The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants. Anesthesia Analg. 2019, 21, 631–640. [Google Scholar] [CrossRef] [PubMed]
  56. Liao, H.-C.; Chiang, C.-C.; Niu, D.-M.; Wang, C.-H.; Kao, S.-M.; Tsai, F.-J.; Huang, Y.-H.; Liu, H.-C.; Huang, C.-K.; Gao, H.-J.; et al. Detecting multiple lysosomal storage diseases by tandem mass spectrometry—A national newborn screening program in Taiwan. Clin. Chim. Acta 2014, 431, 80–86. [Google Scholar] [CrossRef]
  57. Jongco, A.M.; Sporter, R.; Hon, E.; Elshaigi, O.; Zhang, S.; Daian, F.; Bae, E.; Innamorato, A.; Capo, C.; Navetta-Modrov, B.; et al. Characterization of Infants with Idiopathic Transient and Persistent T Cell Lymphopenia Identified by Newborn Screening—A Single-Center Experience in New York State. J. Clin. Immunol. 2021, 41, 610–620. [Google Scholar] [CrossRef]
  58. Gans, M.D.; Gavrilova, T. Retrospective Analysis of a New York Newborn Screen Severe Combined Immunodeficiency Referral Center. J. Clin. Immunol. 2020, 40, 456–465. [Google Scholar] [CrossRef]
  59. Roussel, A.; Canaan, S.; Egloff, M.-P.; Rivière, M.; Dupuis, L.; Verger, R.; Cambillau, C. Crystal Structure of Human Gastric Lipase and Model of Lysosomal Acid Lipase, Two Lipolytic Enzymes of Medical Interest. J. Biol. Chem. 1999, 274, 16995–17002. [Google Scholar] [CrossRef] [Green Version]
  60. Roussel, A.; Miled, N.; Berti-Dupuis, L.; Rivière, M.; Spinelli, S.; Berna, P.; Gruber, V.; Verger, R.; Cambillau, C. Crystal Structure of the Open Form of Dog Gastric Lipase in Complex with a Phosphonate Inhibitor. J. Biol. Chem. 2002, 277, 2266–2274. [Google Scholar] [CrossRef]
  61. Saito, S.; Ohno, K.; Suzuki, T.; Sakuraba, H. Structural bases of Wolman disease and cholesteryl ester storage disease. Mol. Genet. Metab. 2012, 105, 244–248. [Google Scholar] [CrossRef] [PubMed]
  62. Rajamohan, F.; Reyes, A.R.; Tu, M.; Nedoma, N.L.; Hoth, L.R.; Schwaid, A.G.; Kurumbail, R.G.; Ward, J.; Han, S. Crystal structure of human lysosomal acid lipase and its implications in cholesteryl ester storage disease. J. Lipid Res. 2020, 61, 1192–1202. [Google Scholar] [CrossRef] [PubMed]
  63. Rajamohan, F.; Reyes, A.R.; Ruangsiriluk, W.; Hoth, L.R.; Han, S.; Caspers, N.; Tu, M.; Ward, J.; Kurumbail, R.G. Expression and functional characterization of human lysosomal acid lipase gene (LIPA) mutation responsible for cholesteryl ester storage disease (CESD) phenotype. Protein Expr. Purif. 2015, 110, 22–29. [Google Scholar] [CrossRef] [PubMed]
  64. Pajed, L.; Wagner, C.; Taschler, U.; Schreiber, R.; Kolleritsch, S.; Fawzy, N.; Pototschnig, I.; Schoiswohl, G.; Pusch, L.-M.; Wieser, B.I.; et al. Hepatocyte-specific deletion of lysosomal acid lipase leads to cholesteryl ester but not triglyceride or retinyl ester accumulation. J. Biol. Chem. 2019, 294, 9118–9133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Du, H.; Duanmu, M.; Witte, D.; Grabowski, G.A. Targeted disruption of the mouse lysosomal acid lipase gene: Long-term survival with massive cholesteryl ester and triglyceride storage. Hum. Mol. Genet. 1998, 7, 1347–1354. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Du, H.; Heur, M.; Duanmu, M.; Grabowski, G.A.; Hui, D.Y.; Witte, D.P.; Mishra, J. Lysosomal acid lipase-deficient mice: Depletion of white and brown fat, severe hepatosplenomegaly, and shortened life span. J. Lipid Res. 2001, 42, 489–500. [Google Scholar] [CrossRef] [PubMed]
  67. Grumet, L.; Eichmann, T.O.; Taschler, U.; Zierler, K.A.; Leopold, C.; Moustafa, T.; Radovic, B.; Romauch, M.; Yan, C.; Du, H.; et al. Lysosomal Acid Lipase Hydrolyzes Retinyl Ester and Affects Retinoid Turnover. J. Biol. Chem. 2016, 291, 17977–17987. [Google Scholar] [CrossRef] [Green Version]
  68. Qu, P.; Du, H.; Wilkes, D.S.; Yan, C. Critical Roles of Lysosomal Acid Lipase in T Cell Development and Function. Am. J. Pathol. 2009, 174, 944–956. [Google Scholar] [CrossRef] [Green Version]
  69. Qu, P.; Shelley, W.C.; Yoder, M.C.; Wu, L.; Du, H.; Yan, C. Critical Roles of Lysosomal Acid Lipase in Myelopoiesis. Am. J. Pathol. 2010, 176, 2394–2404. [Google Scholar] [CrossRef]
  70. Zhao, T.; Ding, X.; Du, H.; Yan, C. Myeloid-Derived Suppressor Cells Are Involved in Lysosomal Acid Lipase Deficiency–Induced Endothelial Cell Dysfunctions. J. Immunol. 2014, 193, 1942–1953. [Google Scholar] [CrossRef]
  71. Ding, X.; Zhao, T.; Lee, C.-C.; Yan, C.; Du, H. Lysosomal Acid Lipase Deficiency Controls T- and B-Regulatory Cell Homeostasis in the Lymph Nodes of Mice with Human Cancer Xenotransplants. Am. J. Pathol. 2021, 191, 353–367. [Google Scholar] [CrossRef] [PubMed]
  72. Zhao, T.; Liu, S.; Ding, X.; Johnson, E.M.; Hanna, N.H.; Singh, K.; Sen, C.K.; Wan, J.; Du, H.; Yan, C. Lysosomal acid lipase, CSF1R and PD-L1 determine functions of CD11c+ myeloid-derived suppressor cells. JCI Insight 2022, 7, e156623. [Google Scholar] [CrossRef] [PubMed]
  73. Zhao, T.; Ding, X.; Yan, C.; Du, H. Endothelial Rab7 GTPase mediates tumor growth and metastasis in lysosomal acid lipase–deficient mice. J. Biol. Chem. 2017, 292, 19198–19208. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Helderman, R.C.; Whitney, D.G.; Duta-Mare, M.; Akhmetshina, A.; Vujic, N.; Jayapalan, S.; Nyman, J.S.; Misra, B.B.; Rosen, C.J.; Czech, M.P.; et al. Loss of function of lysosomal acid lipase (LAL) profoundly impacts osteoblastogenesis and increases fracture risk in humans. Bone 2021, 148, 115946. [Google Scholar] [CrossRef]
  75. Leopold, C.; Duta-Mare, M.; Sachdev, V.; Goeritzer, M.; Maresch, L.K.; Kolb, D.; Reicher, H.; Wagner, B.; Stojakovic, T.; Ruelicke, T.; et al. Hepatocyte-specific lysosomal acid lipase deficiency protects mice from diet-induced obesity but promotes hepatic inflammation. Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids 2019, 1864, 500–511. [Google Scholar] [CrossRef]
  76. Qu, P.; Yan, C.; Blum, J.S.; Kapur, R.; Du, H. Myeloid-Specific Expression of Human Lysosomal Acid Lipase Corrects Malformation and Malfunction of Myeloid-Derived Suppressor Cells in lal−/− Mice. J. Immunol. 2011, 187, 3854–3866. [Google Scholar] [CrossRef] [Green Version]
  77. Du, H.; Zhao, T.; Ding, X.; Yan, C. Hepatocyte-Specific Expression of Human Lysosome Acid Lipase Corrects Liver Inflammation and Tumor Metastasis in lal−/− Mice. Am. J. Pathol. 2015, 185, 2379–2389. [Google Scholar] [CrossRef]
  78. Zhao, T.; Ding, X.; Du, H.; Yan, C. Lung Epithelial Cell–Specific Expression of Human Lysosomal Acid Lipase Ameliorates Lung Inflammation and Tumor Metastasis in Lipa−/− Mice. Am. J. Pathol. 2016, 186, 2183–2192. [Google Scholar] [CrossRef] [Green Version]
  79. Yamazaki, S.; Iwama, A.; Takayanagi, S.-I.; Eto, K.; Ema, H.; Nakauchi, H. TGF-β as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 2009, 113, 1250–1256. [Google Scholar] [CrossRef] [Green Version]
  80. Nguyen, H.D.; Ticer, T.; Bastian, D.; Kuril, S.; Li, H.; Du, H.; Yan, C.; Yu, X.-Z. Lysosomal Acid Lipase Is Required for Donor T Cells to Induce Graft-versus-Host Disease. Cell Rep. 2020, 33, 108316. [Google Scholar] [CrossRef]
  81. Zhao, T.; Du, H.; Ding, X.; Walls, K.; Yan, C. Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal−/− mice. Oncogene 2015, 34, 1938–1948. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Elleder, M.; Chlumská, A.; Hyánek, J.; Poupětová, H.; Ledvinová, J.; Maas, S.; Lohse, P. Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer. J. Hepatol. 2000, 32, 528–534. [Google Scholar] [CrossRef] [PubMed]
  83. Elleder, M.; Chlumska, A.; Ledvinová, J.; Poupětová, H. Testis—A Novel Storage Site in Human Cholesteryl Ester Storage Disease. Autopsy Report of an Adult Case with a Long-Standing Subclinical Course Complicated by Accelerated Atherosclerosis and Liver Carcinoma. Virchows Arch. 2000, 436, 82–87. [Google Scholar] [CrossRef] [PubMed]
  84. Liu, X.; Viswanadhapalli, S.; Kumar, S.; Lee, T.-K.; Moore, A.; Ma, S.; Chen, L.; Hsieh, M.; Li, M.; Sareddy, G.R.; et al. Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. Nat. Cancer 2022, 3, 866–884. [Google Scholar] [CrossRef]
  85. Lopresti, M.W.; Cui, W.; Abernathy, B.E.; Fredrickson, G.; Barrow, F.; Desai, A.S.; Revelo, X.S.; Mashek, D.G. Hepatic lysosomal acid lipase overexpression worsens hepatic inflammation in mice fed a Western diet. J. Lipid Res. 2021, 62, 100133. [Google Scholar] [CrossRef]
  86. Sun, Y.; Xu, Y.-H.; Du, H.; Quinn, B.; Liou, B.; Stanton, L.; Inskeep, V.; Ran, H.; Jakubowitz, P.; Grilliot, N.; et al. Reversal of advanced disease in lysosomal acid lipase deficient mice: A model for lysosomal acid lipase deficiency disease. Mol. Genet. Metab. 2014, 112, 229–241. [Google Scholar] [CrossRef]
  87. Kuriwaki, K.; Yoshida, H. Morphological characteristics of lipid accumulation in liver-constituting cells of acid lipase deficiency rats (Wolman’s disease model rats). Pathol. Int. 1999, 49, 291–297. [Google Scholar] [CrossRef]
  88. Du, H.; Levine, M.; Ganesa, C.; Witte, D.P.; Cole, E.S.; Grabowski, G.A. The Role of Mannosylated Enzyme and the Mannose Receptor in Enzyme Replacement Therapy. Am. J. Hum. Genet. 2005, 77, 1061–1074. [Google Scholar] [CrossRef] [Green Version]
  89. Du, H.; Cameron, T.L.; Garger, S.J.; Pogue, G.P.; Hamm, L.A.; White, E.; Hanley, K.M.; Grabowski, G.A. Wolman disease/cholesteryl ester storage disease: Efficacy of plant-produced human lysosomal acid lipase in mice. J. Lipid Res. 2008, 49, 1646–1657. [Google Scholar] [CrossRef] [Green Version]
  90. Du, H.; Heur, M.; Witte, D.P.; Ameis, D.; Grabowski, G.A. Lysosomal Acid Lipase Deficiency: Correction of Lipid Storage by Adenovirus-Mediated Gene Transfer in Mice. Hum. Gene Ther. 2002, 13, 1361–1372. [Google Scholar] [CrossRef]
  91. Lam, P.; Ashbrook, A.; Zygmunt, D.A.; Yan, C.; Du, H.; Martin, P.T. Therapeutic Efficacy of rscAAVrh74.miniCMV.LIPA Gene Therapy in a Mouse Model of Lysosomal Acid Lipase Deficiency. Mol. Ther.-Methods Clin. Dev. 2022, 26, 413–426. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. The LIPA gene mutations.
Table 1. The LIPA gene mutations.
StudyYearCountryAuthorPopulationn
Total		ChildrenAdultsE8SJM
c.G894A		MethodRef.
Homo
Zygote		Hetero
Zygote
High-risk screening2022SloveniaSuster, UFH669669030NGS/Sanger[20]
2021ItalyPasta, AHypoapolipoproteinemia or mixed hyperlipemia74074NRNRSanger[21]
2021RussiaMiroshnikova, VVSuspected FH59283110NGS/Sanger[22]
2019U.K.Ashfield-Watt, PFH with no mutation in LDLR, ApoB, and Pcsk9.663066303Sanger+TaqMan[23]
2016NetherlandsSjouke, BFH with no mutation in LDLR and ApoB2766321302Sanger[24]
2015U.S.Pullinger, CRDyslipidemia1357Combined06Sanger[25]
2013GermanyMuntoni, SSelected cohorts2023Not described010Sanger[26]
2007GermanyMuntoni, SSelected cohorts2023Not described010Allele-selective PCR[27]
Confirmed cases2017ItalyPisciotta, LLAL-D-confirmed patients1614245Sanger[28]
FH, Familial Hypercholesterolemia.
Table
Table 4. Phenotype of Lipa-deficient mice.
Table 4. Phenotype of Lipa-deficient mice.
CategoryGenotypeLAL ActivityPhenotypeYearRef.
Global KOLipa(-/-)Deficient↑CE1998[65]
Lipa(-/-)Deficient↑CE; →TG2001[66]
Lipa(-/-)Deficient→TG2016[67]
Lipa(-/-)DeficientT cell defect2009[68]
Lipa(-/-)DeficientAnemia; ↑Sca-1(+)c-kit(+); ↑GMP2010[69]
Lipa(-/-)Deficient↑MDSC2014[70]
Lipa(-/-)Deficient↑T- and B-regulatory cell homeostasis2021[71]
Lipa(-/-)Deficient↑MDSC function2022[72]
Lipa(-/-)Deficient↑EC transmigration;
↓Apoptosis;
↑Angiogenesis;
↑Tube formation.		2014[70]
Lipa(-/-)Deficient↑Endothelial Rab72017[73]
Lipa(-/-)Deficient↓Osteoblastogenesis2021[74]
Conditional KO (cKO)Alb-Cre; cKOLiver-specific deficient↑Hepatic inflammation; ↓Diet-induced obesity2019[75]
Alb-Cre; cKOLiver-specific deficient↑CE; →TG; →RA (normal chow); ↑CE; ↓TG; ↓RA (VitA/HFD)2019[64]
Tg/KOc-fms-tg/Lipa(-/-)Myeloid-specific expressionNormalized MDSC function2011[76]
Lap-tg/Lipa(-/-)Liver-specific expressionNormalized melanoma metastasis2015[77]
CCSP-tg/Lipa(-/-)Lung alveolar type II epithelial cell-specific expression Normalized tumor metastasis;Normalized Lung inflammation2016[78]
Alb, albumin; CCSP, Clara cell secretory protein; cKO, conditional knockout; GMP, Guanosine monophosphate; HFD, high-fat diet; Lap, liver-activated promoter; MDSC, myeloid-derived suppressor cells; Tg, transgenic; VitA, vitamin A; ↑, increase; ↓, decrease; →, no change.
Table
Table 5. Preclinical studies.
Table 5. Preclinical studies.
MethodYearEnzyme/VectorDoseRouteRef.
ERT2005phLAL, chLAL3.95 mg/kgIntraperitoneal[88]
2008hLAL (Nicotiana benthamiana)1.65–6.65 mg/kgIntraperitoneal[89]
2014hLAL0.8–10 mg/kgIntravenous[86]
GT2003Adenovirus3 × 108 PFUIntravenous[90]
2021AAV85 × 1011 vc/mouseIntravenous[85]
2022scAAVrh748.4 × 1013 vg/kgIntravenous[91]
AAV, adeno-associated virus; ch, Chinese hamster ovary; ERT, enzyme replacement therapy; GT, gene therapy; p, Pichia pastoris.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Mashima, R.; Takada, S. Lysosomal Acid Lipase Deficiency: Genetics, Screening, and Preclinical Study. Int. J. Mol. Sci. 2022, 23, 15549. https://doi.org/10.3390/ijms232415549

AMA Style

Mashima R, Takada S. Lysosomal Acid Lipase Deficiency: Genetics, Screening, and Preclinical Study. International Journal of Molecular Sciences. 2022; 23(24):15549. https://doi.org/10.3390/ijms232415549

Chicago/Turabian Style

Mashima, Ryuichi, and Shuji Takada. 2022. "Lysosomal Acid Lipase Deficiency: Genetics, Screening, and Preclinical Study" International Journal of Molecular Sciences 23, no. 24: 15549. https://doi.org/10.3390/ijms232415549

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop